EU PRIME status for Mereo’s brittle bone drug
Pharma Times | November 14, 2017
London, UK-based Mereo BioPharma’s experimental drug targeting brittle bone disease has been designated PRIME status by the European Medicines Agency (EMA). Brittle bone disease, or osteoporosis imperfect (OI), is a rare genetic disorder characterized by fragile bones and reduced bone mass resulting in bones that break easily, loose joints and weakened teeth.